Vorobjova T, Nilsson I, Kull K, Maaroos H I, Covacci A, Wadström T, Uibo R
Department of Immunology, University of Tartu, Hospital of Oncology, Estonia.
Eur J Gastroenterol Hepatol. 1998 Jan;10(1):41-6. doi: 10.1097/00042737-199801000-00008.
The prevalence of antibodies to CagA protein, associated with the risk of developing gastric cancer (GC), was studied in an Estonian adult population with a high prevalence of Helicobacter pylori (HP) infection and in a group of GC patients.
In a representative sample of a random adult population from the South Estonian town of Karksi-Nuia, containing 199 subjects (86 M, 113 F, mean age 42.4) and in 45 (22 M, 23 F, mean age 64.5) consecutive patients with gastric adenocarcinoma, recruited during the periods 1986-87 and 1995-96 in the Hospital of Oncology, University of Tartu, anti-CagA IgG antibodies were determined by enzyme-linked immunosorbent assay (ELISA) using a recombinant fragment of CagA protein. The occurrence of anti-CagA IgG in ELISA was compared with immunoblot results for 141 subjects.
Seropositivity to acid glycine extracted cell surface proteins of HP was 85% in the population and 91% in GC patients (p = 0.39). Anti-CagA IgG antibodies were present in 63% of the population and in 87% of GC patients (p = 0.004). The highest prevalence of anti-CagA IgG in the population sample occurred in the age group 20-29 (76%). A comparison of anti-CagA positivity evaluated by using ELISA and immunoblot showed an agreement of results in 80% of cases.
HP seropositivity was similarly high in the Estonian random adult population sample and in GC patients, however, the prevalence of anti-CagA IgG was significantly higher in GC patients. Moreover, persons aged 20-29 years in the population possess the highest prevalence of anti-CagA IgG and should be given further attention with respect to the development of GC later in life.
在幽门螺杆菌（HP）感染率高的爱沙尼亚成年人群和一组胃癌患者中，研究与胃癌发生风险相关的抗CagA蛋白抗体的流行情况。
在爱沙尼亚南部城镇卡尔西-努亚的随机成年人群的代表性样本中，有199名受试者（86名男性，113名女性，平均年龄42.4岁），以及在塔尔图大学肿瘤医院1986 - 87年和1995 - 96年期间招募的45名（22名男性，23名女性，平均年龄64.5岁）连续的胃腺癌患者中，使用CagA蛋白的重组片段通过酶联免疫吸附测定（ELISA）来测定抗CagA IgG抗体。将ELISA中抗CagA IgG的出现情况与141名受试者的免疫印迹结果进行比较。
人群中对HP酸甘氨酸提取的细胞表面蛋白的血清阳性率为85%，胃癌患者中为91%（p = 0.39）。63%的人群和87%的胃癌患者中存在抗CagA IgG抗体（p = 0.004）。人群样本中抗CagA IgG的最高流行率出现在20 - 29岁年龄组（76%）。通过ELISA和免疫印迹评估的抗CagA阳性率比较显示，80%的病例结果一致。
在爱沙尼亚随机成年人群样本和胃癌患者中，HP血清阳性率同样高，然而，抗CagA IgG的流行率在胃癌患者中显著更高。此外，人群中20 - 29岁的人抗CagA IgG的流行率最高，在其晚年胃癌发生方面应给予进一步关注。
